{"id":25389,"date":"2015-04-09T03:27:02","date_gmt":"2015-04-09T01:27:02","guid":{"rendered":"https:\/\/renewable-carbon.eu\/news\/?p=25389"},"modified":"2015-04-07T15:37:31","modified_gmt":"2015-04-07T13:37:31","slug":"biovation-launches-bioarmour-blood-pressure-cuff-shield","status":"publish","type":"post","link":"https:\/\/renewable-carbon.eu\/news\/biovation-launches-bioarmour-blood-pressure-cuff-shield\/","title":{"rendered":"Biovation launches Bioarmour\u2122 Blood Pressure Cuff Shield"},"content":{"rendered":"

\"blood-pressure-cuff-shield\"Biovation has launched the BioArmour Blood Pressure Cuff Shield (BPCS) to mitigate the spread of infectious pathogens from blood pressure cuffs. This first-in-class medical product offers a multi-use barrier for prevention of hospital acquired infections (HAIs). The BPCS has been designed, tested and validated over a two-year cycle, and is now available in European, Canadian and all non-US markets. BioArmour is the first in a suite of infection and pathogen control products from Biovation.<\/strong><\/p>\n

Biovation is a technology design and manufacturing company that produces advanced, non-woven fiber products with integrated antimicrobial properties for packaging, healthcare, specialty niche roll goods and wipes products and other specialty advanced material end products. BioArmour was developed and tested in close collaboration with a large hospital system to proactively provide solutions for the mitigation of HAIs.<\/p>\n

The easy-to-use BioArmour BPCS is a disposable antimicrobial hygienic barrier that attaches to the blood pressure cuff to prevent direct contact of the cuff with the patient\u2019s skin. The latex-free shield material is composed of a sustainable biopolymer impregnated with antimicrobial and antifungal agents to mitigate the propagation of a wide spectrum of pathogens in controlled release fashion. Contaminant pathogens \u2013 including MRSA, VRE, c. difficile and others \u2013 are mitigated by the blood pressure cuff shield, allowing for multi-patient use over a 24-hour period.<\/p>\n

In lab testing, the BioArmour BPCS has been shown to kill up to 99.99% of tested microorganisms.\u00a0 The BPCS is manufactured with green technology and a sustainable biopolymer, with an industry-leading 74% biocontent.\u00a0 Its slim profile does not adversely impact accuracy of the blood pressure measurement data.\u00a0 And, the BPCS provides another tool for risk mitigation for hospitals and healthcare facilities with proactive measures for infectious disease reduction and control.\u00a0 This cost-effective system requires no staff maintenance or disinfection between patients and is targeted for in-patient, physician offices, hospice and nursing home facilities and emergency medical services.<\/p>\n

\u201cOur BioArmour\u00a0Blood Pressure Cuff Shield is a proactive measure that helps hospitals and healthcare facilities support their infectious disease reduction and control efforts,\u201d says Biovation Chief Executive Officer Kerem Durdag. \u201cIt is an easy-to-use and cost-effective tool that contributes to patient health and safety. The proprietary manufacturing technology we have employed sets a benchmark for our products in our pipeline.\u201d<\/p>\n

Sciessent partnered with Biovation to develop the antimicrobial technology. \u201cThe BioArmour Blood Pressure Cuff Shield infuses our world-class antimicrobial solutions into Biovation\u2019s biopolymer fibers to result in a safe, non-leaching product with broad-spectrum efficacy,\u201d says Lise Moloney, Director of Business Development \u2013 Healthcare, Sciessent. \u201cWe\u2019re proud to have partnered with Biovation to bring this industry-leading product to market.\u201d<\/p>\n

The BioArmour BPCS has been registered a CE Class I medical device marked for distribution in the EU. As a medical product, it is available for sale in Canada and all other non-US countries. It is currently undergoing testing for US FDA approval, which is anticipated to be received in late summer 2015.<\/p>\n

 <\/p>\n

About Sciessent, LLC<\/h3>\n

Sciessent is a leading provider of customized antimicrobial solutions that enhance the value of customers\u2019 products. Agion antimicrobial solutions from Sciessent have been incorporated into a wide range of healthcare, industrial and consumer applications, including medical devices such as central-venous catheters and IV access ports, drinking-water applications like water filters and ice-making equipment, and textiles and apparel. The company\u2019s brands include Agion, Agion Active and Sciessent Lava and are based on naturally occurring elements. Sciessent customers include leading international brands including Vygon, Medegen, Scotsman, Everpure, Follett, Honeywell, UnderArmour, Adidas, Reebok and Skechers.<\/p>\n

About Biovation II, LLC<\/h3>\n

Biovation is a technology design and manufacturing company that manufactures advanced non-woven fiber products with integrated antimicrobial properties for packaging, healthcare, custom advanced material OEM products, and other specialty scalable applications. Biovation has extensive experience with green and sustainable biopolymers such as polylactic acid, which comes from cornstarch. It is a portfolio company of Anania & Associates Investment Company (www.anania.biz), a Maine-based private equity fund that invests in small, well-managed businesses.<\/p>\n

 <\/p>\n

Contact<\/p>\n

Keri Seitz
\nphone: +1.207.633.0616 x 27
\neMail: kseitz@biovation.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Biovation has launched the BioArmour Blood Pressure Cuff Shield (BPCS) to mitigate the spread of infectious pathogens from blood pressure cuffs. This first-in-class medical product offers a multi-use barrier for prevention of hospital acquired infections (HAIs). The BPCS has been designed, tested and validated over a two-year cycle, and is now available in European, Canadian […]<\/p>\n","protected":false},"author":59,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"","nova_meta_subtitle":"","footnotes":""},"categories":[5572],"tags":[],"supplier":[2374],"class_list":["post-25389","post","type-post","status-publish","format-standard","hentry","category-bio-based","supplier-biovation-llc"],"_links":{"self":[{"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/posts\/25389","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/users\/59"}],"replies":[{"embeddable":true,"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/comments?post=25389"}],"version-history":[{"count":0,"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/posts\/25389\/revisions"}],"wp:attachment":[{"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/media?parent=25389"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/categories?post=25389"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/tags?post=25389"},{"taxonomy":"supplier","embeddable":true,"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/supplier?post=25389"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}